Ananda Developments' Medicines to be Tested in Groundbreaking Epilepsy Trials

Proactive - Interviews for investors

Ananda Developments Finance Director Jeremy Sturgess-Smith joined Steve Darling from Proactive to announce significant advancements for the company. Two of Ananda’s patent-pending cannabinoid medicines, MRX2 and MRX2T, will be used in two Phase IIIa epilepsy clinical trials, co-funded by the National Institute for Health and Care Research (NIHR) and the NHS. The trials, conducted by investigators at University College London and Great Ormond Street Hospital, will involve up to 500 patients and represent the world’s first double-blind randomized controlled trials to investigate the combined use of cannabidiol (CBD) and tetrahydrocannabinol (THC) for epilepsy. These will also be the first to evaluate such treatments for both children and adults with difficult-to-treat epilepsies. Sturgess shared that the MRX formulations will serve as the investigational medicinal products for these ground-breaking trials, which aim to support a marketing authorization application for MRX2 and MRX2T. Should the trials yield positive results, Ananda plans to advance further regulatory and commercial development activities for these medicines. The trials will assess the safety and efficacy of the specific cannabidiol and CBD plus THC formulations in patients suffering from two forms of treatment-resistant epilepsy. Favorable results could pave the way for submission to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and other regulatory bodies, moving Ananda one step closer to introducing innovative cannabinoid treatments for epilepsy. #proactiveinvestors #anandadevelopmentsplc #aqse #ana #EpilepsyResearch #CannabinoidMedicine #ClinicalTrials #CBDTherapy #PharmaInnovation #NIHR #Healthcare #EpilepsyTreatment#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews